News Quantified

ARVN – arvinas, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Selective Estrogen Receptor Degrader (SERDs) Market Research Report 2025-2030 Featuring AstraZeneca, Eli Lilly, EnhancedBio, Olema Oncology, Radius Therapeutics, and Roche [Yahoo! Finance]

Arvinas, Inc. (ARVN): A Bull Case Theory [Yahoo! Finance]

JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra [Yahoo! Finance]

FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo [Yahoo! Finance]

Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment [Yahoo! Finance]

-1.1%

BEAT

-6.8%

BEAT

-11.6%

BEAT

-11.6%

BEAT

Leerink Partners

Leerink Partners

Form 8-K ARVINAS, INC. For: Jul 09

Form 8-K ARVINAS, INC. For: Jun 25

Form 4 ARVINAS, INC. For: Jun 25 Filed by: AGARWAL SUNIL

Form 4 ARVINAS, INC. For: Jun 25 Filed by: Smaldone Alsup Laurie

Form 4 ARVINAS, INC. For: Jun 25 Filed by: Morrison Briggs

Top News Gainers

3/16 Form S-8 ARVINAS, INC. 18.8%

11/6 Form 424B5 ARVINAS, INC. 15.1%

6/4 Bayer teams up with biotech firm Arvinas in deal worth up to $750 million [Reuters (UK)] 11.3%

10/23 Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders 10.5%

11/27 Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference 8.8%

3/24 Form 4 ARVINAS, INC. For: Mar 23 Filed by: Houston John G 7.4%

7/25 Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk 7.3%

11/12 Form 8-K ARVINAS, INC. For: Nov 06 6.9%

7/25 Form 8-K ARVINAS, INC. For: Jul 24 5.9%

9/12 Arvinas Inc (NASDAQ: ARVN) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating on the stock. 5.8%

Top News Decliners

3/16 Q4/2019 12/31/2019 EPS -0.560 ZacksConsensus N/A ActVsEst N/A - N/A -18.4%

3/20 Form 4 ARVINAS, INC. For: Mar 18 Filed by: Margus Bradley Albert -11.5%

8/22 Arvinas Inc (NASDAQ: ARVN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.3%

8/5 Q2/2019 6/30/2019 EPS -0.550 ZacksConsensus N/A ActVsEst N/A - N/A -7.9%

10/1 Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio -7.1%

3/10 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $52.00 price target on the stock. -7.1%

2/6 Form 8-K ARVINAS, INC. For: Jan 31 -6.3%

7/31 Form 3 ARVINAS, INC. For: Jul 29 Filed by: Peck Ronald -5.1%

7/16 Form 8-K ARVINAS, INC. For: Jul 15 -4.8%

10/7 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day